Atea Pharmaceuticals Completes Patient Enrollment in Phase 3 C-FORWARD Trial Evaluating Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus
Atea Pharmaceuticals (AVIR) Upgraded to Buy: Here's What You Should Know
Are Medical Stocks Lagging Atea Pharmaceuticals (AVIR) This Year?
Atea Pharmaceuticals: I'm Optimistic Ahead Of Critical HPV Catalyst
Atea Pharmaceuticals Presents New Drug-Drug Interaction Results Supporting Potential Best-in-Class Profile of the Regimen of Bemnifosbuvir and Ruzasvir for the Treatment of Hepatitis C Virus at EASL Congress 2026
Down 25% in 4 Weeks, Here's Why Atea Pharmaceuticals (AVIR) Looks Ripe for a Turnaround
Atea Pharmaceuticals to Present Three Abstracts at EASL 2026 Congress Highlighting Progress Across Viral Hepatitis Pipeline
Atea Pharmaceuticals, Inc. (AVIR) Q1 2026 Earnings Call Transcript
Atea Pharmaceuticals Q1 Earnings Call Highlights
Atea Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update
Atea Pharmaceuticals to Host First Quarter 2026 Financial Results and Business Update Conference Call on May 12, 2026
Atea Pharmaceuticals (NASDAQ:AVIR) vs. Trevi Therapeutics (NASDAQ:TRVI) Financial Survey
Atea Pharmaceuticals Q4 Earnings Call Highlights
Atea Pharmaceuticals, Inc. (AVIR) Q4 2025 Earnings Call Transcript
Atea Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
Atea Pharmaceuticals to Host Fourth Quarter and Full Year 2025 Financial Results and Business Update Conference Call on March 5, 2026
Atea Pharmaceuticals Presents Preclinical Results Supporting First-in-Class Potential of AT-587 for Treatment of Hepatitis E Virus at CROI 2026
BML Capital Management LLC Cuts Holdings in Atea Pharmaceuticals, Inc. $AVIR
Atea Pharmaceuticals, Inc. (AVIR) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Atea Pharmaceuticals to Highlight 2026 Strategic Priorities at the 44th Annual J.P. Morgan Healthcare Conference
Atea Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference
Atea Pharmaceuticals (NASDAQ:AVIR) Stock Price Down 1.4% – Here’s What Happened
Rapt Therapeutics (NASDAQ:RAPT) & Atea Pharmaceuticals (NASDAQ:AVIR) Head-To-Head Contrast
Atea Pharmaceuticals: Potential Best-In-Class HCV Cure With Pivotal Readouts In 2026
Atea Pharmaceuticals Completes Patient Enrollment in North American Phase 3 Trial Evaluating Regimen of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus
Atea Pharmaceuticals to Present at the 8th Annual Evercore Healthcare Conference
Atea Pharmaceuticals, Inc. (AVIR) Discusses Next-Generation Hepatitis C Treatment Developments and Clinical Advancements Transcript
Atea Pharmaceuticals, Inc. (AVIR) Q3 2025 Earnings Call Transcript
Atea Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update
Atea Pharmaceuticals Presents New Data Supporting the Fixed-Dose Combination of Bemnifosbuvir and Ruzasvir as a Potential Best-in-Class Regimen for Treatment of Hepatitis C Virus Infection at The Liver Meeting® 2025
Atea Pharmaceuticals to Host Third Quarter 2025 Financial Results and Business Update Conference Call on November 12, 2025
Atea Pharmaceuticals to Host Virtual HCV KOL Panel Event on November 13, 2025
Atea Pharmaceuticals to Present New Data Supporting Combination of Bemnifosbuvir and Ruzasvir as Potential Best-in-Class Regimen for Treatment of Hepatitis C Virus Infection at The Liver Meeting® 2025
Atea Pharmaceuticals, Inc. (AVIR) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript
Atea Pharmaceuticals to Present at the Morgan Stanley 23rd Annual Global Healthcare Conference
Atea Pharmaceuticals, Inc. (AVIR) Q2 2025 Earnings Call Transcript
Atea (AVIR) Q2 Loss Narrows 8%
Atea Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update
Atea Pharmaceuticals to Host Second Quarter 2025 Financial Results and Business Update Conference Call on August 7, 2025
Atea Pharmaceuticals Announces Continued Advancement of Global Phase 3 HCV Program with Dosing of First Patient in C-FORWARD Outside North America
Atea Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update
Atea Pharmaceuticals Announces Full Results from Phase 2 Study of Regimen of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus (HCV) Presented at EASL Congress 2025
Atea Pharmaceuticals to Host Virtual HCV KOL Panel on May 14, 2025
Atea Pharmaceuticals to Present New Data Showcasing Potential Best-in-Class Regimen of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus at EASL Congress 2025
Atea Pharmaceuticals Appoints Howard H. Berman to Board of Directors and Announces Share Repurchase Program
Atea Pharmaceuticals Announces Dosing of First Patient in C-BEYOND, Phase 3 Study Evaluating Regimen of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus
Driver Notifies Atea Pharmaceuticals of Withdrawal of Notice of Nomination
Atea Pharmaceuticals Highlights Actions Underway to Enhance Shareholder Value
The Radoff-JEC Group Nominates Three Highly Qualified Candidates for Election to the Atea Pharmaceuticals Board of Directors
Atea Pharmaceuticals Issues Statement Regarding Director Nominations